These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28903503)

  • 1. Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines.
    Kim L; Rha B; Abramson JS; Anderson LJ; Byington CL; Chen GL; DeVincenzo J; Edwards KM; Englund JA; Falsey AR; Griffin MR; Karron RA; Martin KG; Meissner HC; Munoz FM; Pavia AT; Piedra PA; Schaffner W; Simões EAF; Singleton R; Talbot HK; Walsh EE; Zucker JR; Gerber SI
    Clin Infect Dis; 2017 Sep; 65(6):1020-1025. PubMed ID: 28903503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.
    Wright PF; Karron RA; Belshe RB; Shi JR; Randolph VB; Collins PL; O'Shea AF; Gruber WC; Murphy BR
    Vaccine; 2007 Oct; 25(42):7372-8. PubMed ID: 17868959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in RSV vaccine research and development - A global agenda.
    Higgins D; Trujillo C; Keech C
    Vaccine; 2016 Jun; 34(26):2870-2875. PubMed ID: 27105562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of respiratory syncytial virus vaccine development.
    Polack FP; Karron RA
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S65-73. PubMed ID: 14730272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory Syncytial Virus Seasonality - United States, 2014-2017.
    Rose EB; Wheatley A; Langley G; Gerber S; Haynes A
    MMWR Morb Mortal Wkly Rep; 2018 Jan; 67(2):71-76. PubMed ID: 29346336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.
    Herring WL; Zhang Y; Shinde V; Stoddard J; Talbird SE; Rosen B
    Vaccine; 2022 Jan; 40(3):483-493. PubMed ID: 34933763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
    Munoz FM
    Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in and the potential of vaccines for respiratory syncytial virus.
    Jorquera PA; Oakley KE; Tripp RA
    Expert Rev Respir Med; 2013 Aug; 7(4):411-27. PubMed ID: 23964629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Passive and active immunization against respiratory syncytial virus for the young and old.
    Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational sciences approach to RSV vaccine development.
    Kurzweil V; Tang R; Galinski M; Wang K; Zuo F; Cherukuri A; Gasser RA; Malkin E; Sifakis F; Mendel DB; Esser MT
    Expert Rev Vaccines; 2013 Sep; 12(9):1047-60. PubMed ID: 24053398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the development of subunit-based RSV vaccines.
    Jaberolansar N; Toth I; Young PR; Skwarczynski M
    Expert Rev Vaccines; 2016; 15(1):53-68. PubMed ID: 26506139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody.
    Huang K; Wu H
    Microbiol Spectr; 2014 Aug; 2(4):AID-0014-2014. PubMed ID: 26104207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop.
    Roberts JN; Graham BS; Karron RA; Munoz FM; Falsey AR; Anderson LJ; Marshall V; Kim S; Beeler JA
    Vaccine; 2016 Sep; 34(41):4843-4849. PubMed ID: 27566900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RSV associated hospitalizations in children in Karachi, Pakistan: Implications for vaccine prevention strategies.
    Ali A; Yousafzai MT; Waris R; Jafri F; Aziz F; Abbasi IN; Zaidi A
    J Med Virol; 2017 Jul; 89(7):1151-1157. PubMed ID: 28092107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Hot Pursuit of the First Vaccine Against Respiratory Syncytial Virus.
    Kim JY; Chang J
    Yonsei Med J; 2016 Jul; 57(4):809-16. PubMed ID: 27189271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and epidemiologic features of respiratory syncytial virus.
    Hall CB; Simőes EA; Anderson LJ
    Curr Top Microbiol Immunol; 2013; 372():39-57. PubMed ID: 24362683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current practices for respiratory syncytial virus surveillance across the EU/EEA Member States, 2017.
    Mollers M; Barnadas C; Broberg EK; Penttinen P; ; Teirlinck AC; Fischer TK;
    Euro Surveill; 2019 Oct; 24(40):. PubMed ID: 31595876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA
    Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RSV vaccine use--the missing data.
    Drysdale SB; Sande CJ; Green CA; Pollard AJ
    Expert Rev Vaccines; 2016; 15(2):149-52. PubMed ID: 26636902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory syncytial virus: A continuing culprit and conundrum.
    Hall CB
    J Pediatr; 1999 Aug; 135(2 Pt 2):2-7. PubMed ID: 10431132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.